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Abstract - Despite aggressive strategies are now 
available to reduce LDL-cholesterol, the risk of 
cardiovascular events in patients with coronary artery 
disease remains substantial. Several preclinical and 
clinical studies have shown that drug therapy 
ultimately leads to a regression of the angiographic 
lesions but also results in a reduction in cardiovascular 
events. The dramatic failure of clinical trials evaluating 
the cholesterol ester transfer protein (CEPT) inhibitors, 
torcetrapib and dalcetrapib, has led to considerable 
doubt about the value of the current strategy to raise 
high-density lipoprotein cholesterol (HDL-C) as a 
treatment for cardiovascular disease. These clinical 
results, as well as animal studies, have revealed the 
complexity of HDL metabolism, assessing a more 
important role of functional quality compared to 
circulating quantity of HDL. As a result, HDL-based 
therapeutic interventions that maintain or enhance 
HDL functionality, such as improving its main 
property, the reverse cholesterol transport, require 
closer investigation. In this review, we will discuss 
HDL metabolism and function, clinical-trial data 
available for HDL-raising agents, and potential 
strategies for future HDL-based therapies. 
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Transport, Cholesterol Efflux, Apolipoprotein AI, HDL 
 
I.INTRODUCTION 
In the last ten years, several therapeutic 
interventions have been developed to reduce Low 
Density Lipoprotein-Cholesterol (LDL-C) to meet the 
gold standard levels as suggest by the current 
guidelines [1]. However, the cardiovascular risk 
remains still significant, approaching an annual risk of 
9% in patients with established coronary artery disease 
(CAD), thus novel strategies are needed for targeting 
this residual cardiovascular risk [2]. In this regard, 
early epidemiological studies have identified low levels 
of high-density lipoprotein cholesterol (HDL-C, <1.0 
mmol/l or 40 mg/dl) to be an independent risk factor 
for cardiovascular disease  [3]. Therefore, raising 
HDL-C levels provides an important strategy for 
addressing the residual cardiovascular risk in these 
patients. Experimental studies have identified several 
beneficial functions of HDL that seems to be 
independent of its primary cholesterol removal. They 
include endothelial [4, 5], antiapoptotic [6], 
antithrombotic [7], antioxidant [7], and anti-
inflammatory effects[8], all of which may contribute to 
its anti-atherosclerotic properties.Several important 
lifestyle changes, such as aerobic exercise, smoking 
cessation, weight loss reduction, ‘‘low-fat’’ diet and 
high intake of n-3 polyunsaturated fats, mild to 
moderate alcohol intake, etc. can help to raise HDL-C 
levels [9]. Unfortunately, these strategies are often not 
enough to reach the suggested HDL-C levels. Current 
pharmacological approaches include nicotinic acid, 
fibrates, statins, thiazolidinediones, bile acid 
sequestrants in high doses have been employed, but the 
side effects and the high variability in raising HDL, 
significantly hinder their wide use[3, 9]. Furthermore, 
the disappointing results of the ILLUMINATE trial 
with the cholesteryl ester transfer protein (CETP) 
inhibitor, torcetrapib [10], the early termination of dal-
OUTCOMES with dalcetrapib because of no benefits 
[11],  strongly suggest that the “quality” of HDL is also 
extremely important and novel and more effective 
strategies are needed to adequately increase HDL-C. 
Moreover, a recent meta-analysis [12] has shown that 
niacin, CEPT inhibitors and fibrates, targeted at 
increasing HDL-C levels, were not associated with 
significantly reduced risk of all cause mortality and 
coronary heart disease mortality. 
The major difference between the LDL and 
HDL is their protein moiety. Apolipoprotein A-I 
(ApoA-I) is the major protein constituent of HDL [13], 
defining its size and shape, solubilizing its lipid 
components, removing cholesterol from peripheral 
cells, activating the LCAT enzyme, and delivering the 
resulting cholesterol esters to the liver, a phenomenon 
called reverse cholesterol transport (RCT). Raising 
ApoA-I levels and then nascent HDL, seems to be one 
of the most promising strategy [13, 14]. Several 
approaches have been attempted in recent years to 
increase HDL-C levels, including the direct 
administration of synthetic HDL [15] or ApoA-I, as a 
whole [16] or as a mimetic peptide [17]. Furthermore, 
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pre-clinical [18] and clinical [19] studies have 
previously shown that intravascular infusions of 
synthetic HDL containing a genetic variant of ApoA-I, 
ApoA-I Milano (ApoA-IM), inhibit progression and 
induce rapid regression and remodelling of 
atherosclerosis. Also ApoA-I gene transfection results 
in sustained expression of functional ApoA-I and 
increased plasma HDL cholesterol[20]. More 
important, this increase is associated with plaque 
regression and stabilisation[21]. 
II.  REVERSE CHOLESTEROL TRANSPORT AND 
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL 
FUNCTIONS 
Although the atheroprotective properties of 
HDL-Chave not been directly compared, it is likely 
that RCT plays a crucial role in these anti-atherogenic 
effects [22]. The RCT hypothesis proposes that HDL-C 
accepts cholesterol from the periphery, such as arterial 
wall cells, and deliver it to the liver for excretion via 
the bile salts. In 1990 the pioneering work of 
Badimonet al. [23] employed HDL-C as a therapeutic 
agent: it was the first preclinical evidence that plaque 
regression is feasible, showing that HDL-C infusion 
promotes regression of pre-existing lesions in a rabbit 
model of atherosclerosis. Other HDL-C elevating 
interventions corroborated this finding in animals [18] 
and in humans [15, 19]. The life cycle of HDL begins 
with apolipoprotein A-I (ApoA-I) being synthesized by 
the liver and, after interaction with hepatic ATP-
binding cassette transporter 1 (ABCA1), is secreted 
into plasma as lipid-poor ApoA-I [14, 22]. The 
maturation process starts by acquisition of cholesterol 
and phospholipids (PLs) via ABCA1-mediated efflux 
from the liver and the transfer of cholesterol, PLs, and 
apolipoproteins from chylomicrons and vey low-
density lipoproteins (VLDL) during lipoprotein-lipase-
mediated lipolysis to form nascent pre-β-HDLs [13]. 
Additional cholesterol and PLs are acquired from cells 
in extrahepatic tissues via ABCA1-mediated efflux, 
progressively generating more cholesterol-enriched 
particles. The enzyme lecithin-cholesterol acyl 
transferase (LCAT), carried on HDLs, esterifies the 
free cholesterol (FC) tocholesteryl ester (CE), which 
migrate to the core of the HDL-particle to form mature 
HDLs that can acquire additional lipid via ABCG1and 
SR-BI-mediated efflux [13, 14, 22] (Figure 1).Thus, 
pharmacological modulation of any of the key players 
in RCT may be of great importance for cholesterol 
accumulation and/or removal, ultimately modifying the 
atherosclerotic process. 
 
III.  NIACIN, CEPT INHIBITORS AND FIBRATES: 
IT HAS BEEN ONLY AN ILLUSION! 
Niacin 
Niacin, also known as vitamin B3 and 
nicotinic acid, is a physiological precursor of two 
coenzymes (nicotinamide adenine dinucleotide and 
nicotinamide adenine dinucleotide phosphate) involved 
in oxidoreductive reactions and energy metabolism 
[24].The chronic deficiency of niacin leads to the onset 
of Pellagra, a disease characterized by dementia, 
dermatitis, and diarrhea [25]. Niacin reduces all 
proatherogenic lipid and lipoprotein particles, 
including total cholesterol, triglycerides, VLDL, LDL, 
Lp(a) and small dense LDL particles [26, 27] and it is, 
therefore, the most potent available drug to increase 
antiatherogenic HDL levels [27]. Moreover, niacin 
increases larger HDL2 subfractions and selectively 
increases apoA-I-containing HDL particles, a mediator 
of RCT [28-30]. There are several pathways related to 
increase of HDL in patients treated with niacin. By 
inhibiting the surface expression of hepatocyte β chain 
ATP synthase [31] (a recently recognized HDL holo-
particle receptor), niacin decreases the uptake of HDL-
apoAI without affecting the de-novo synthesis of 
apoAI in Hep-G2 cells [32, 33]. Niacin, therefore, 
could down-regulates cell surface expression of the β 
chain ATP synthase, leading to hepatic removal of 
HDL through holoparticle endocytosis, retaining 
increased HDL-apoAI particles in the bloodstream. At 
the same time, niacin increases apoA-I lipidation and 
HDL biogenesis by enhancing lipid efflux through a 
DR4-mediated transcription of ABCA1 gene in 
hepatocytes [27, 34]. Regarding the effect on 
triglycerides, niacin inhibited hepatocyte triglyceride 
synthesis and increased intracellular post-translational 
apoB degradation resulting in decreased secretion of 
apoB and apoB-containing VLDL and LDL particles 
[35]. In particular, niacin directly and non-
competitively inhibited hepatocyte microsomal 
DGAT2, a key enzyme that catalyzes the final reaction 
in triglyceride synthesis as the target site for niacin’s 
action on triglyceride synthesis [36]. In this way, 
niacin, by decreasing atherogenic VLDL/LDL particles 
and increasing antiatherogenic HDL, contribute to 
decrease atherosclerosis. Moreover, niacin seems to 
exert also pleiotropic effects. It has been recently 
reported that niacin significantly inhibited reactive 
oxygen species (ROS) production, LDL oxidation, 
redox-sensitive vascular cell adhesion molecule-1 
(VCAM-1) and monocyte chemotactic protein-1 
(MCP-1) mRNA expression, and monocyte adhesion in 
human aortic endothelial cells [26], suggesting that this 
drug inhibits vascular inflammation by decreasing 
endothelial ROS production, and subsequent 
expression of critical inflammatory VCAM-1 and 
MCP-1 genes, that have an important role in the 
development of atherogenesis. In addition to the 
vascular effects, recent studies have also shown that 
niacin inhibits atherosclerosis in mice via its receptor 
GPR109A expression in macrophages and immune 
cells [37, 38]. 
The most important data to sustain the use of 
niacin derive from the Coronary Drug Project (CDP), a 
pre-statin study evaluating niacin monotherapy in 
patients with prior myocardial infarction. Niacin was 
associated with a 27% reduction in the incidence of 
nonfatal re-infarction at 6 years [39], and all-cause 
mortality was reduced by 11% at 15 years [40]. 
Different pharmaceutical formulations have been 
created to avoid the adverse effects, in particular 
flushing, with the addition of prostaglandins inhibitors. 
Translational Medicine @ UniSa - ISSN 2239-9747 2015, 12(6): 29-40 
 
31 
Università degli Studi di Salerno 
Its therapeutic use has been considered for decades in 
the prevention and treatment of atherosclerosis but, in 
the last years, negative outcomes of recent clinical 
trials, have questioned its effectiveness [41].Two 
recent studies have evaluated the role of niacin in the 
reduction of cardiovascular risk. The results of AIM-
HIGH trial (Atherothrombosis Intervention in 
Metabolic Syndrome With Low HDL/High 
Triglycerides: Impact on Global Health Outcomes) 
showed, in an interim analysis, no cardiovascular 
benefit from taking extended-release niacin when 
added to therapy with a simvastatin plus ezetimibe. In 
fact, there was a greater risk of ischemic stroke, which 
did not reach statistical significance with a early 
discontinuation of the study [42]. HPS2-THRIVE trial, 
instead, which evaluated the CordaptiveTM/statin 
combination versus statin alone, was recently stopped 
after only 3.9 years because of serious adverse events 
in the treated arm [43].On the other hand, a recent 
meta-analysis of 11 clinical trials, including AIM-
HIGH, in about 10000 patients, showed that niacin 
therapy was associated with a significant reduction in 
major Cardiovascular disease and coronary heart 
disease events [44]. Accordingly, there is a need for 
further studies designed to evaluate the role of niacin in 
combination with the new cholesterol-lowering drugs 
in reducing the incidence of CVD events. 
Cholesteryl ester transfer protein inhibitors 
Considering the role of CETP in RCT, which 
favors transfer of cholesterol from HDL to LDL, it was 
thought that a pharmacological action against this 
enzyme could reduce the risk of atherosclerosis, and 
synthetic inhibitors were developed to restore a 
favourable lipoprotein profile by increasing HDL-C 
concentration and lowering LDL-C concentration. 
Torcetrapib was the first molecule to be designed as 
CETPinhibitor, and evaluated in phase III of 
ILLUMINATE trial [45]. The study was stopped due to 
a global overall mortality in patients treated with this 
drug, although HDL-C concentration had increased. 
Subsequent analyses showed that this negative effect 
was due to activation of the renin-angiotensin-
aldosterone system, increasing blood pressure, but also 
to direct vascular endothelium toxicity [46]. Despite 
the failure of ILLUMINATE trial, new drugs were 
synthesized: dalcetrapib, evacetrapib, and anacetrapib. 
Dalcetrapib is a CETP inhibitor that raised HDL 
cholesterol levels by approximately 30%, without 
significant effects on LDL cholesterol levels, blood 
pressure, or circulating neurohormones but with 
possible beneficial vascular effects,  including the 
reduction in total vessel enlargement over 24 
months[47, 48]. In dal-OUTCOMES study, were 
evaluated the effects of dalcetrapib on cardiovascular 
risk among patients with a recent acute coronary 
syndrome. The addition of dalcetrapib to standard 
therapy after an acute coronary syndrome raised the 
levels of HDL cholesterol and apo-AI, with minimal 
effects on levels of LDL cholesterol and apo-B. 
Nevertheless, the risk of major cardiovascular 
outcomes was not significantly altered [11]. As regards 
the other two drugs, are still ongoing trials to 
demonstrate their effectiveness. The safety of 
evacetrapib has been demonstrated in a phase II study 
[49], to evaluate its efficacy and safety versus placebo 
in high-risk patients for vascular disease will end in 
January 2016. Two phase III trials are currently 
ongoing for anacetrapib: the DEFINE trial [50] and the 
REVEAL HSP-3 TIMI-55 trial (Randomized 
Evaluation of the Effects of Anacetrapib through Lipid 
Modification). In addition, a recent paper shown that 
after the withdrawal of active treatment, anacetrapib 
plasma lipid changes and drug levels decreased to 
approximately 40% of on-treatment trough levels at 12 
weeks after dosing, but modest HDL cholesterol 
elevations and low drug concentrations were still 
detectable 2 to 4 years after the last dosing [51]. In the 
DEFINE trial, conducted in patients at high risk for 
coronary heart disease, anacetrapib reduced LDL 
cholesterol levels by 39.8% after 24 weeks compared 
with placebo, and demonstrated an acceptable safety 
profile. Furthermore, a raise of 138.1% in HDL 
cholesterol levels, with no alterations in blood pressure, 
aldosterone or electrolytes has been reported. The 
REVEAL HSP-3 TIMI-55 trial, which includes 30,000 
coronary patients treated with statins, will end in 2017. 
Inhibiting CETP could have an anti-atherogenic effect 
because it inhibits the movement of cholesteryl esters 
into apo-B-containing lipoproteins with a decreasing of 
the cholesteryl esters-laden LDL available for uptake 
by macrophages for foam cell formation. However, 
inhibiting this HDL ‘rearrangement", may diminish 
apoA-I and lipid-poor HDL pools available for 
peripheral cholesterol efflux or may decrease the 
possibility of cholesteryl esters being transferred to 
apo-B-containing lipoproteins for excretion by the 
liver, thus defining a pro-atherogenic effect. 
Furthermore, it is known that there are different 
subtypes of LDL that can be separated in two 
phenotypes differing, in particular, in size, density, and 
atherogenicity. These phenotypes have been called 
‘pattern A’ (or larger LDL) and ‘pattern B’ (or smaller 
LDL) [52]. LDL size correlates positively with plasma 
HDL levels [53] and several studies have demonstrated 
that the phenotype B is correlated with an increased 
cardiovascular risk [52].Therefore, through inhibition 
of CETP, could increase the level of LDL smaller that 
would increase the risk of atherosclerosis. 
Fibric acid derivatives 
Peroxisome proliferator-activated receptors 
(PPARs) are nuclear transcription receptors that 
regulate lipid and carbohydrate homeostasis; three 
isoforms (α,  and ß/δ) are known.  Fibric acid 
derivatives or fibrates, are agonists of α isoform of 
PPARs. They have several functions on lipids levels in 
bloodstream, among others: increase HDL-C levels (by 
10%-20%), modestly lower LDL-C levels (by 10%-
15%), and substantially lower levels of triglycerides 
(by 40%-50%)[54, 55]. Moreover, these drugs improve 
lipoprotein plasma profile and insulin sensitivity while 
enhance vasomotor reactivity, and reduce inflammation 
[56]. Several clinical studies have assessed the impact 
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of fibrates on clinical outcomes in primary and 
secondary prevention (the Helsinki Heart Study, the 
VA-HIT study, etc).  Despite a 34% reduction in major 
coronary events at 5 years, as shown by the Helsinki 
Heart Study, fibrates have failed to reduce overall 
mortality in the general population [12]. In the VA-HIT 
trial, treatment with gemfibrozil was associated with 
reduction in CVD events. The study showed a 
reduction in the combined outcome of cardiovascular 
death, non-fatal myocardial infarction, and stroke of 24 
percent, attributed to a modest increase (6%) in HDL-C 
levels [55]. Some evidence indicate that the benefits 
seen in the VA-HIT cohort may be partly due to 
additional effects of fibrates on apolipoprotein 
synthesis and lipoprotein metabolism [57]. The 
combination of fibrates, particularly gemfibrozil, with 
statins requires caution and monitoring of creatine 
kinase levels because of the risk for myotoxicity, 
including rhabdomyolysis [58]. Because of variable-
outcome study results and problems linked to the 
safety, the precise role of fibrate treatment remains 
uncertain but is reasonable that fenofibrate and 
bezafibrate could be useful for diabetes or metabolic 
syndrome and gemfibrozil could be useful for patients 
with dyslipidemia [58, 59]. A new class of drugs, 
called glitazars, are dual agonists acting on both α and 
 isoforms and are able to impact lipid and 
carbohydrate metabolism. Positive effects on lipid 
metabolism and insulin-sensitizing make possible their 
use in metabolic syndrome in patients with low HDL. 
In the phase II of SYNCHRONY study [60] was 
evaluated, in type II diabetics patients, the safety and 
positive impact on lipoprotein profile of aleglitazar. A 
phase III study (AleCardio), including patients with 
type 2 diabetes hospitalized for acute coronary 
syndrome, was halted for increase in incidence of bone 
fractures, heart failure, and gastrointestinal bleeding. 
IV. RECOMBINANT HDL INFUSION AND APO-AI 
INCREASING STRATEGIES: A LOOK TO A 
CLOSE FUTURE? 
In 1990, the pioneering study of Badimon et 
al. employed HDL as therapeutic agent. It was the first 
preclinical evidence that plaque regression is feasible, 
showing that HDL cholesterol infusion regressed pre-
existing lesions in a rabbit model of atherosclerosis 
[23]. Other LDL-lowering interventions [61, 62] 
corroborated this finding in different models [4, 7, 8, 
63], while several HDL-elevating interventions have 
reduced atheroma volume in humans [14]. Intravenous 
administration of liposomic complexes containing 
human proapolipoprotein A-I (the secreted form of 
apoA-I) in patients with familial 
hypercholesterolaemia, led a raise of 30% of fecal 
excretion of cholesterol and biliary acids [64]. Purified 
apoA-I was then combined with soya 
phophatidylcholines and the product was called CSL-
111 that was tested in patients with acute coronary 
syndrome [15]. After a weekly perfusion over 1 month, 
patients treated with CSL-111 had a 3.4% volume 
reduction in the atherosclerotic plaque but was 
associated with mild, self-limiting transaminase 
elevation, clinically well tolerated. Recently, second 
generation products have emerged, such as CSL-112 
and CER-001, currently evaluated in ongoing studies. 
In the presence of human plasma, CSL-112 was 
significantly more potent than native HDL at 
enhancing cholesterol efflux from macrophages, and 
the efflux elevation was predominantly via the ABCA1 
transporter [65]. Phase 2 trials of CSL-112 are 
currently under way in stable coronary artery disease 
and ACS patients. At the same time, administration of 
CER-001 [66, 67] caused elevations in plasma 
cholesterol, as well as, total and free cholesterol in 
HDL fraction suggesting increased reverse cholesterol 
transport. In the 80s, in a Town of Northern Italy 
(Limone sul Garda), in three members of a family with 
significant hypertriglyceridaemia and low HDL-C 
concentrations, without any manifestation of 
atherosclerosis, was discovered a new type of apoA-I, 
called apoA-I Milano (apoA-IM). It is a natural variant 
of apoA-I characterized by a cysteine for arginine 
substitution at position 173 of the primary sequence. 
ApoA-IM carriers have much less atherosclerosis than 
expected from their very low HDL cholesterol levels, 
suggesting that the variant might be protective [18]. 
Despite a similar effect on acute plaque regression, the 
infusion of HDL-Milano exerts superior anti-
inflammatory and plaque stabilizing effects than HDL 
wild-type in the short term [68]. Synthetic HDLs, made 
with a recombinant form of apoA-IM and phospholipids 
given in two injections four days apart, are effective in 
inducing the regression of atherosclerotic plaques, in 
enhancing reverse cholesterol transport [69], in 
reducing global inflammation [69, 70], in preventing 
arterial restenosis, limiting cardiac dysfunction after 
ischemia/reperfusion injury [18, 19], and even in 
reversing aortic stenosis [71]. 
ApoA-I mimetic peptide 
Recently, novel HDL-directed target therapies 
have been created.  FAMP (Fukuoka University ApoA-
I Mimetic Peptide) is a drug that mimics human apoA-I 
without complexing with Phospholipids. It enhances 
the function of HDL, and suppresses aortic plaque 
formation in apoE-knockout mice fed a high-fat diet 
[72]. FAMP markedly increases pre-β HDL and overall 
cholesterol efflux from peripheral tissues. It may 
enhance cellular cholesterol efflux trough 
internalization and transcytosis in macrophages or 
aortic endothelial cells, and the removal of intracellular 
cholesterol. Therefore, is described a physical 
interactions between FAMP and ABCA1 to transport 
intracellular cholesterol to the circulation, and this 
latter mechanism may be predominant. Another apoA-I 
mimetic peptide, 4F, removes plasma oxidized lipids 
(PLs and fatty acids) and improves the anti-
inflammatory properties of HDL [73]. Because of the 
very high cost of the latter, have been developed 
transgenic tomato plants expressing an apoA-I mimetic 
peptide, 6F. After 13 weeks of treatment with this drug, 
there was a reduction in the percent of aorta with 
lesions than the control group [17]. 
Apo AI gene therapy 
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The biggest limitations in the use of HDL are 
the costs and the inability to maintain these stable 
levels of HDL after injection. In a previous study we 
have compared the safety and effectiveness of a single 
administration of AAV8-based vectors encoding 
human ApoA-I, driven by cytomegalovirus promoter, 
after intraportal and intramuscular injection over a 
period of 16 weeks [20]. Hepatic and muscular gene 
transfers of human ApoA-I in ApoA-I–null mice using 
AAV8 vectors resulted in sustained expression of 
functional ApoA-I and increased plasma HDL 
cholesterol. These data suggest that intramuscular 
AAV8- mediated gene transfer of human ApoA-I is as 
effective as intraportal vector delivery in increasing 
circulating ApoA-I and HDL-cholesterol levels. As 
such, intramuscular gene delivery of ApoA-I may serve 
as an appealing minimally invasive technique in the 
management of atherosclerosis. Furthermore, these 
strategies resulted also into a significant reduced 
progression of established atherosclerotic lesions in an 
animal model of atherosclerosis [74]. Therefore, de 
novo ApoA-I production is an important driving force 
behind HDL elevation and gene transfer by viral vector 
seems a promising strategy to pursue. 
 
V.  RATIONALE TO INCREASE APO-AI 
Clinical and basic research has proven that not 
all HDL particles possess antiatherogenic properties 
since chronic inflammatory processes render HDL 
particles dysfunctional [75, 76] with alterations of their 
structure and metabolism. Some of the already used 
pharmacological agents do not increase the 
“protective” HDL. From the physiological point of 
view, raising ApoA-I should provide the way to 
increase nascent empty HDL [73]. Preclinical studies 
[18, 71, 74] strengthen this hypothesis.  
 
VI.  CONCLUSIONS 
Current guidelines on lipid management focus 
on reducing the amount of circulating LDL cholesterol 
through the body because of the availability of 
powerful LDL-lowering medications, namely the 
statins, which are ideal agents for long-term use and 
have proven their effectiveness in large randomized 
clinical trials. However, it is also widely accepted that 
other aspects of lipid metabolism could produce 
important therapeutic targets to control the epidemic of 
atherosclerosis and consequent cardiovascular disease. 
Interventions on the HDL side of a patient’s lipid 
profile have been typically based on the concept that 
raising HDL cholesterol levels will reduces 
atherosclerosis. This expectation comes from 
epidemiological observations consistently showing an 
inverse correlation between HDL cholesterol levels and 
cardiovascular event rates (i.e., myocardial infarctions). 
Nonetheless, direct evidence that raising HDL 
cholesterol levels will reduce cardiovascular risk is 
scarce and incomplete. A suggestive hypothesis could 
be that low levels of HDL-C did not constitute a risk 
factor per se, but only an indirect marker of 
cardiovascular risk, as they are often associated with 
obesity, impaired glucose tolerance and diabetes. This 
could be the reason for the absence of a clear efficacy 
of the drugs tested to date, as the therapeutic target 
does not appear to be the correct one. In particular, 
despite of high hopes on the use of CETP inhibitors, 
the occurrence of side effects linked to the molecule 
and, at the same time, to the pharmacologic class, 
advises against the use of such drugs. The failure of the 
trials maybe related to a "clogging" of HDL, which 
would no longer be able to effectually carry out their 
amount of cholesterol. To date, then, the real effective 
treatment lowering HDL-C remains the non-
pharmacological therapy, represented by regular 
physical activity. Furthermore, current strategies still 
fail to increase HDL cholesterol, thus novel and more 
promising intervention, such as direct injection of 
“good quality” HDL or over-expression of ApoA-I, are 
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HDL formation: HDL particles start out as 
apolipoproteins produced by the liver, called apoAI. 
Precursor molecules are released in HDL called pre-B-
HDL, incorporating small quantities of cholesterol and 
lipids, especially phospholipids (PL). ABC proteins 
(ATP-Binging Cassette Transports) transport various 
molecules across extra- and intra-cellular membranes. 
Cholesterol from non-hepatic peripheral tissues is 
transferred to HDL by the ABCA1. ABCG1 and 
ABCG4 are necessary for the further lipidation. These 
receptors are required for spherical particles HDL 
formation. The free cholesterol (FC) is converted to 




Translational Medicine @ UniSa - ISSN 2239-9747 2015, 12(6): 29-40 
 
39 




Schematic view of RCT: ApoA-I is responsible for the 
metabolic fate of HDL cholesterol HDLs and is 
synthesized by the liver. HDLs are released to the 
circulation as a lipid-poor HDL (nascent HDL), mostly 
formed by ApoA-I and phospholipids (PL). Through 
their metabolic maturation, HDLs interact with the 
ABCA1, ABCG1 and also SR-B1 receptor in the 
macrophage surface and peripheral tissue increasing 
their lipid content by taking PLs and cholesterol 
becoming spherical HDL. The cholesterol of the HDLs 
is transported to the liver, via the scavenger receptor 
class B, type I (SR-BI), for further metabolization and 
excretion to the intestines in the form of bile acids and 
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Therapeutic Interventions to increase RCT: This is a 
schematic view of the possible strategies to increase 
Apo AI functions, via Apo AI mimetic peptides, 
ApoA-I Milano infusions, ApoA-I viral transfection, 
recombinant HDL infusion. These interventions may 
result in an increased RCT, thus removing cholesterol 
from the body and reducing atherosclerosis 
 
